AAUM (Average Assets Under Management) of ₹3,097.34 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 71.2% | 72.1% | ▲ +0.9% |
| Healthcare Services | 27.9% | 24.2% | ▼ -3.7% |
| Healthcare Equipment & Supplies | 0.5% | 2.2% | ▲ +1.7% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 72.1% | 71.3% | ▼ -0.9% |
| Healthcare Services | 24.2% | 22.1% | ▼ -2.0% |
| Healthcare Equipment & Supplies | 2.2% | 2.4% | ▲ +0.2% |
| Retailing | 0.0% | 1.0% | ▲ +1.0% |
Comparing Aug 2026 → Sep 2026
| # | Stock | Sector | Weight (Sep 2026) |
|---|---|---|---|
| 1 | Entero Healthcare Solutions Ltd ₹35.37 Cr |
Retailing | 1.01% |
| # | Stock | Sector | Last Weight (Aug 2026) |
|---|---|---|---|
| 1 | Fortis Healthcare Limited ₹78.62 Cr |
Healthcare Services | 2.37% |
| 2 | Ajanta Pharma Limited ₹38.97 Cr |
Pharmaceuticals & Biotechnology | 1.18% |
| # | Stock | Sector | Aug 2026 | Sep 2026 | Change |
|---|---|---|---|---|---|
| 1 | Apollo Hospitals Enterprise Limited ₹129.18 Cr |
Healthcare Services | 1.39% | 3.69% | +2.30% |
| 2 | Alkem Laboratories Limited ₹162.58 Cr |
Pharmaceuticals & Biotechnology | 3.06% | 4.64% | +1.58% |
| 3 | Dr. Reddy's Laboratories Limited ₹111.58 Cr |
Pharmaceuticals & Biotechnology | 1.90% | 3.19% | +1.29% |
| 4 | Gland Pharma Limited ₹62.32 Cr |
Pharmaceuticals & Biotechnology | 1.09% | 1.78% | +0.69% |
| 5 | Molbio Diagnostics Ltd. ₹70.42 Cr |
Healthcare Equipment & Supplies | 1.77% | 2.01% | +0.24% |
| 6 | Cipla Limited ₹145.37 Cr |
Pharmaceuticals & Biotechnology | 3.94% | 4.15% | +0.21% |
| 7 | Symbiotec Pharmalab Limited ₹47.64 Cr |
Pharmaceuticals & Biotechnology | 1.21% | 1.36% | +0.15% |
| 8 | Shilpa Medicare Ltd ₹113.18 Cr |
Pharmaceuticals & Biotechnology | 3.10% | 3.23% | +0.13% |
| 9 | Wockhardt Limited ₹59.95 Cr |
Pharmaceuticals & Biotechnology | 1.61% | 1.71% | +0.10% |
| 10 | Jubilant Pharmova Limited ₹32.67 Cr |
Pharmaceuticals & Biotechnology | 0.85% | 0.93% | +0.08% |
| # | Stock | Sector | Aug 2026 | Sep 2026 | Change |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited ₹289.76 Cr |
Pharmaceuticals & Biotechnology | 8.94% | 8.28% | -0.66% |
| 2 | Lupin Limited ₹124.15 Cr |
Pharmaceuticals & Biotechnology | 4.04% | 3.55% | -0.49% |
| 3 | Neuland Laboratories Limited ₹113.51 Cr |
Pharmaceuticals & Biotechnology | 3.70% | 3.24% | -0.46% |
| 4 | Max Healthcare Institute Limited ₹126.42 Cr |
Healthcare Services | 4.06% | 3.61% | -0.45% |
| 5 | Torrent Pharmaceuticals Limited ₹127.91 Cr |
Pharmaceuticals & Biotechnology | 4.08% | 3.65% | -0.43% |
| 6 | Anthem Biosciences Limited ₹110.90 Cr |
Pharmaceuticals & Biotechnology | 3.48% | 3.17% | -0.31% |
| 7 | Rubicon Research Limited ₹88.16 Cr |
Pharmaceuticals & Biotechnology | 2.82% | 2.52% | -0.30% |
| 8 | Aster DM Healthcare Limited ₹124.51 Cr |
Healthcare Services | 3.84% | 3.56% | -0.28% |
| 9 | Biocon Limited ₹51.49 Cr |
Pharmaceuticals & Biotechnology | 1.73% | 1.47% | -0.26% |
| 10 | Jupiter Life Line Hospitals Limited ₹58.95 Cr |
Healthcare Services | 1.94% | 1.68% | -0.26% |
38 stocks — Sep 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹328.63 Cr |
Pharmaceuticals & Biotechnology |
9.39%
|
|
| 2 |
₹289.76 Cr |
Pharmaceuticals & Biotechnology |
8.28%
|
|
| 3 |
₹162.58 Cr |
Pharmaceuticals & Biotechnology |
4.64%
|
|
| 4 |
₹145.37 Cr |
Pharmaceuticals & Biotechnology |
4.15%
|
|
| 5 |
₹129.18 Cr |
Healthcare Services |
3.69%
|
|
| 6 |
₹127.91 Cr |
Pharmaceuticals & Biotechnology |
3.65%
|
|
| 7 |
₹126.42 Cr |
Healthcare Services |
3.61%
|
|
| 8 |
₹124.51 Cr |
Healthcare Services |
3.56%
|
|
| 9 |
₹124.15 Cr |
Pharmaceuticals & Biotechnology |
3.55%
|
|
| 10 |
₹113.51 Cr |
Pharmaceuticals & Biotechnology |
3.24%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.